STAGE IIIC LUNG CANCER AJCC V8

This early-stage study tests whether giving a single, precise dose of radiation after surgery for non-small cell lung cancer is safe and feasible. Standard radiation requires many small doses over weeks, which can damage healthy lung tissue. The study involves 50 patients who had…

This early-phase study tests a combination of four drugs (ensartinib, carboplatin, pemetrexed, and bevacizumab) in people with advanced ALK-positive non-small cell lung cancer that has spread or returned. The goal is to find the best dose and check for side effects. About 12 part…

This early-stage study tests a drug called NBTXR3, which boosts the effects of radiation on cancer cells, in people with non-small cell lung cancer that has returned and cannot be surgically removed. About 34 participants will receive the drug injected into the tumor followed by …

This early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in about 5 people with a specific type of advanced lung cancer (ALK-positive) that has continued to grow despite prior treatment. The main goals are to find the best dose and check for side effec…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagno…

This early-stage trial tests the safety and best dose of a new drug called minnelide when given with the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The study involves about 8 adults whose cancer has spread or cannot be…

This study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes 74 adults with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread to the lung…

This study tests two drugs—niraparib and dostarlimab—together in people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a repair process in cancer cells, while dostarlimab helps the immune system attack them.…

This study tests an online program designed to improve social well-being and emotional support for women with non-small cell lung cancer. About 70 women currently receiving treatment will practice mindfulness, compassion, and emotional processing techniques. The goal is to see if…

This study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with worries and fears about their disease progressing. About 42 participants will try the program, which includes home practice activities, to see if it is practical and he…

This study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite and weight. About 25 participants will take either the drug or a placebo daily and share their exper…